NCT04349475

Brief Summary

This study plans to learn more about how an omega-3 fatty acid supplement effects triglyceride levels in pregnancy. Triglycerides are a type of fat found in your blood. Your body converts extra calories into triglycerides to be stored and used later for energy. It is normal for triglyceride levels to go up during pregnancy however some women have levels that are \~30-40% higher than normal when they reach their third trimester of pregnancy. Having high triglycerides in pregnancy may be related to an increased chance of having a baby that is large for their age. The goal of this study is to determine if taking an omega-3 fatty acid supplement can slow the rise in triglyceride levels later in pregnancy.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for not_applicable pregnancy

Timeline
0mo left

Started Nov 2021

Longer than P75 for not_applicable pregnancy

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 16, 2020

Completed
1.6 years until next milestone

Study Start

First participant enrolled

November 29, 2021

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Expected
Last Updated

May 11, 2026

Status Verified

May 1, 2026

Enrollment Period

4.4 years

First QC Date

April 13, 2020

Last Update Submit

May 7, 2026

Conditions

Keywords

triglyceridesglucoseadiposityAir displacement plethysmographyContinuous glucose monitoring

Outcome Measures

Primary Outcomes (1)

  • Maternal Fasting and Postprandial Triglycerides

    Differences in maternal fasting and postprandial triglycerides between groups

    34 weeks gestational age

Study Arms (2)

Omega 3 Supplementation

EXPERIMENTAL

Supplementation of 4g of DHA/EPA daily

Dietary Supplement: Intervention Omega 3 Supplementation

Safflower Oil Supplement

PLACEBO COMPARATOR

Supplementation of Safflower Oil daily

Dietary Supplement: Control Safflower Oil

Interventions

Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)

Omega 3 Supplementation
Control Safflower OilDIETARY_SUPPLEMENT

Participants will consume 2.5g of a Safflower oil supplement daily

Safflower Oil Supplement

Eligibility Criteria

Age0 Years - 39 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Pregnant women between the ages of 21-39 yrs
  • Pre-pregnancy BMI 28-39
  • Fasting Triglyceride ≥120 mg/dL measured by 15 wks

You may not qualify if:

  • Pre-gestational diabetes or prediabetes
  • History of gestational diabetes,
  • History of pre-eclampsia, spontaneous pre-term delivery, or gestational hypertension \<34wks
  • Tobacco or illicit substance use
  • Chronic steroid use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Colorado/Anschutz Medical Campus

Aurora, Colorado, 80045, United States

Location

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Related Publications (1)

  • Barbour LA, Farabi SS, Friedman JE, Hirsch NM, Reece MS, Van Pelt RE, Hernandez TL. Postprandial Triglycerides Predict Newborn Fat More Strongly than Glucose in Women with Obesity in Early Pregnancy. Obesity (Silver Spring). 2018 Aug;26(8):1347-1356. doi: 10.1002/oby.22246. Epub 2018 Jun 22.

    PMID: 29931812BACKGROUND

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Teri L Hernandez, PhD

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2020

First Posted

April 16, 2020

Study Start

November 29, 2021

Primary Completion

April 30, 2026

Study Completion (Estimated)

May 31, 2026

Last Updated

May 11, 2026

Record last verified: 2026-05

Locations